$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The work of a pathologist may be pretty challenging both in clinical diagnostics and research fields. The evolution of light microscopy in the 18th and 19th century was remarkable. The power of an electron microscope relies primarily on the wavelength of the electrons, which is shorter than light1,2,3. Before the advent of the polyclonal and monoclonal antibodies and their application in immunohistochemistry, TEM played an influential role in diagnosing small round blue cell tumors.
Starting with the 90's of the last century, the immunohistochemical approach has substituted the morphologic tool in diagnostics4. Currently, there are thousands of new polyclonal and monoclonal antibodies directed to antigens of the small round blue cell tumor group4,6,7,8. In the last decade of the highly prolific 20th century and the first decade of the beginning of the 21st century, molecular biology, including fluorescence in situ hybridization, from genomic probes through next-generation sequencing, seems to have superseded the significant application role of immunohistochemistry in several laboratories4. The Food and Drug Administration (FDA) in the United States of America, the Canadian Food Inspection Agency (CFIA) of Canada, the Environmental Protection Agency (EPA), or similar governmental bodies in other countries do not always approve molecular biology protocols9. It seems that there is a lot of information quite challenging to insert in a pathology report that can be used for therapeutic purposes, and the oculate choice of a well-funded and running laboratory information system is critical10. In the meantime, immunohistochemistry has revealed numerous pitfalls, with epithelial tumors showing mesenchymal markers and vice versa11. The epithelial-mesenchymal transition has confused some borders in pathology groups12,13. In the last few years, it has become evident that electron microscopy flourished in several labs worldwide14. In particular, the tissue specimens' turnaround time has decreased from weeks to only 3 days or even less using several protocols approaching the staining with monoclonal or polyclonal antibodies4,10.
Moreover, applying an electronic camera coupled to the electron microscope helped provide the pathologists with a rapid image, which is versatile in different operating systems. Finally, some antibodies, even after antigen retrieval, are challenging to be revealed in some areas of necrosis or autophagy/ischemia-related changes. At the same time, electron microscopy in safe hands can still deliver excellent results and hints for the correct classification of unknown pathologic tumors15.
The pediatric small round blue cell tumor group includes several tumors, mainly neuroblastoma, Wilms tumor or nephroblastoma, rhabdomyosarcoma, and Ewing sarcoma. The molecular biology data relative to the pediatric group of small round blue cell tumors can be overwhelming because of the techniques applied. The small round blue cells may not differ much on routine stains (hematoxylin and eosin staining), and some tumors may have aberrant immunophenotypical features. Advances in molecular biology have been enormous since the discovery of TEM. In the group of small round blue cell tumors, some neoplasms may be more frequently encountered than others, but they need to be considered. Although the papillary renal cell carcinoma is not essentially a small round blue cell tumor but features papillae mostly, it may show some round cell areas that may need to be distinct from other well-known small round blue cell tumors (e.g., Wilms tumor) using several ancillary techniques16. Ultimately, metanephric stromal tumors may also need to be taken into differential diagnosis17. The rhabdoid tumor is a particularly malignant pediatric tumor distinct in the renal and extra-renal subtype18.
Neuroblastoma is one of the most common solid malignancies in infancy and childhood. Neuroblastoma cells are the malignant cells of this solid tumor that arise insidiously from derivatives of the primordial neural crest. Its diagnosis and differential diagnosis may be difficult. Its natural biology has seen remarkable advances in the last couple of decades. The forkhead family of transcription factors is characterized by a distinct "forkhead" domain (FOXO3/FKHRL1). These transcription factors function as a trigger for apoptosis (programmed cell death) through the expression of genes necessary for cell death. FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8, and this complex plays a crucial role in neuroblastoma. Nuclear FOXO3 predicts adverse clinical outcomes and promotes tumor angiogenesis in neuroblastoma7,19. Despite the molecular pathology advances, the Shimada classification remains the standard of practice for any pathologist and pediatric oncologist. It is critical in differentiating between favorable and unfavorable histology20,21,22,23.
The rationale for developing a straightforward protocol for the electron microscopy of tumors suspicious of neuroblastoma is linked to the feasibility and solidity of the ultrastructural examination of the tissue specimen. It is rarely altered by problems commonly encountered using immunohistochemistry. The rationale and protocol have been the basis of several textbooks and scientific contributions to pediatric pathology and electron microscopy4,24,25. This protocol spans the experience of three decades of the author and will focus on a few PSRBCT, emphasizing the personal experience and the literature review.